In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.
first published: Mar 13, 2012 10:50 am
A collection of the most-viewed Moneycontrol videos.
Monday Mayhem in markets| Brent surges 18%, Global markets slide 2-8% | Nifty Set for Gap Down Open
PM Modi Speech: PM Modi Accuses TMC of Insulting President Murmu and Constitution
India Markets Not Cheap Right Now? CIO Rajesh Bhatia Flags Risks
Will AI Replace Financial Advisors? Future of Investing Explained
